Generation Bio GBIO 深 沪
已收盘 09-19 16:00:00 美东时间
5.75
-0.230
-3.85%
华盛通- 最 高6.05
- 今 开5.98
- 成交量 8.19万股
- 最 低 5.75
- 昨 收 5.98
- 总市值 3872.91万
- 52周最高 27.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.004
- 委 比 81.82%
- 总股本 673.55万
- 历史最高 557.20
- 量 比 0.85
- 振 幅 5.02%
- 历史最低 3.004
- 每 手 1
- 风险率 7.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray涨超30%
加密货币交易所Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray隔夜涨超30%，周内涨超90%，特朗普拟将大麻改为低危药物>>
08-14 15:08
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Generation Bio Q2 EPS $(3.12) Misses $(2.62) Estimate, Sales $765.000K Miss $2.139M Estimate
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2.62) by 19.08 percent. This is a 906.45 percent decrease over losses of $(0.31) per share from
08-13 05:38
Generation Bio shares are trading higher after the company announced new data demonstrating that its cell-targeted lipid nanoparticle system selectively delivered siRNA to T cells in non-human primates.
Generation Bio shares are trading higher after the company announced new data d...
08-13 04:25
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
Generation Bio announced new data demonstrating their cell-targeted lipid nanoparticle (ctLNP) system successfully delivered siRNA to T cells in non-human primates, a first in the field. The system showed potent and selective knockdown of beta-2 microglobulin, LAT1, and VAV1, potentially addressing T cell-driven autoimmune diseases. The company reported a cash balance of $141.4 million as of June 30, 2025, and is evaluating strategic alternatives...
08-12 20:05
Generation Bio shares are trading higher after the company announced it has been granted Australian Patent Number 2019210034 titled "Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors (for gene therapy)"
Generation Bio shares are trading higher after the company announced it has bee...
07-26 02:44
Generation Bio shares are trading lower after the company announced a 1-for-10 reverse stock split.
Generation Bio shares are trading lower after the company announced a 1-for-10 ...
07-18 22:51
Generation Bio Announces 1-for-10 Reverse Stock Split
Generation Bio announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq listing requirements. Effective July 21, 2025, every 10 shares will be combined into 1 share, reducing outstanding shares from ~67.3M to ~6.7M. The stock will resume trading on July 22 under the same symbol "GBIO" with a new CUSIP. Adjustments will be made to equity plans, and fractional shares will be paid in cash. The goal is to...
07-18 12:35
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Generation Bio Co. granted 128,600 non-statutory stock options to a new employee on July 1, 2025, under its 2025 Inducement Stock Incentive Plan. The options have an exercise price of $0.32 per share, a 10-year term, and vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter. The company specializes in treating T cell-driven autoimmune diseases by reprogramming T cells to reduce autoreactive cells using lip...
07-07 20:05
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Generation Bio Co. (Nasdaq:GBIO) announced that its CEO, Geoff McDonough, M.D., will present at the Jefferies Global Healthcare Conference on June 4th. The presentation will focus on the company's work to treat T cell-driven autoimmune diseases by reprogramming T cells using lipid nanoparticles (ctLNP) to deliver siRNA, targeting disease-driving genes. A live webcast and replay will be available on the company's investor website. --- Generation...
05-28 10:59
